Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,770 total articles

RoboStrategy, Inc. Lists on NASDAQ Under Ticker “BOT”, Enabling Investors to Access a Portfolio of Robotics and Physical AI Companies in a Single Stock
May 11, 2026
Hana Yamamoto
Press Releases

RoboStrategy, Inc. Lists on NASDAQ Under Ticker “BOT”, Enabling Investors to Access a Portfolio of Robotics and Physical AI Companies in a Single Stock

RoboStrategy, Inc., a closed-end investment fund focusing on robotics and physical AI companies, has begun trading on the NASDAQ under the ticker BOT. The fund offers public investors exposure to a concentrated portfolio of private, pre-IPO, and public robotics firms, bridging the gap between venture capital opportunities and public markets. This d…

BOT
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
Marcus Reed
Press Releases

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences announced preclinical data demonstrating the potential of fatty acid synthase (FASN) inhibitors to reduce sebum production, a key factor in acne. This supports their upcoming Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S., planned to initiate in the second half of 2026. The data will be presented a…

SGMT
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 11, 2026
Leila Farooq
Press Releases

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics announced FDA clearance for an IND to begin Phase 1/2 clinical trials of their oral elraglusib formulation in advanced cancers including metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, aiming to improve patient convenience and drug exposure. The company also revealed plans to study elraglusib in combination with…

ACTU
Hain Celestial Reports Fiscal Third Quarter 2026 Financial Results
May 11, 2026
Priya Menon
Press Releases

Hain Celestial Reports Fiscal Third Quarter 2026 Financial Results

Hain Celestial announced its fiscal third quarter 2026 financial results, reporting a 13% year-over-year decline in net sales to $338 million, with organic net sales down 6%. Despite lower revenues and a net loss of $106 million driven partly by asset impairments and the sale of its North American snacks business, the company improved its financial…

HAIN
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
May 11, 2026
Avery Klein
Press Releases

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

Fractyl Health received authorization to start a Phase 1/2 clinical trial of RJVA-001, its first gene therapy candidate aimed at treating type 2 diabetes by enabling nutrient-responsive GLP-1 expression in the pancreas. This marks the company's advancement to a dual clinical-stage biotech, with RJVA-001 being the first adeno-associated virus-based …

GUTS
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
May 11, 2026
Avery Klein
Press Releases

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau Medical Ltd. announced groundbreaking interim results from their U.S. trial of Alpha DaRT therapy in patients with recurrent glioblastoma. Among the first three patients treated, two showed complete responses with total tumor disappearance, while the third had stable disease and tumor reduction. The treatment was generally well tolerated …

DRTS
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 11, 2026
Hana Yamamoto
Press Releases

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

MBX Biosciences provided preliminary blinded Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, demonstrating mean weight loss of 7% at 8 weeks and a pharmacokinetic profile supportive of once-monthly dosing. The drug was generally well tolerated with minimal gastrointestinal side effects. The company also announced MBX 5765 as …

MBX
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
May 11, 2026
Caleb Monroe
Press Releases

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

Erasca, Inc. announced a clinical collaboration and supply agreement with Merck to conduct the AURORAS-1 study evaluating their investigational pan-RAS molecular glue ERAS-0015 in combination with Merck's KEYTRUDA (pembrolizumab) for RAS-mutant solid tumors. The agreement includes Merck supplying pembrolizumab at no cost and aims to improve treatme…

ERAS
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026
Nina Shah
Press Releases

Rezolute to Participate in Upcoming Investor Conferences

Rezolute, Inc., a late-stage biotechnology company focused on rare diseases related to hyperinsulinism, announced its management will participate in two major upcoming investor conferences. The participation includes fireside chats and one-on-one meetings, aiming to update investors on their developments, including their antibody therapy ersodetug,…

RZLT
Keel Infrastructure Reports First Quarter 2026 Results
May 11, 2026
Maya Rios
Press Releases

Keel Infrastructure Reports First Quarter 2026 Results

Keel Infrastructure Corp., rebranded and redomiciled in the U.S., reported its Q1 2026 financial results highlighting a strategic shift from Bitcoin mining to high-performance computing (HPC) and AI data center infrastructure in North America. The company reported a net loss of $145 million primarily due to operational costs, impairments, and adjus…

KEEL
ARKO Petroleum Corp. Reports First Quarter 2026 Results
May 11, 2026
Nina Shah
Press Releases

ARKO Petroleum Corp. Reports First Quarter 2026 Results

ARKO Petroleum Corp. announced robust financial results for Q1 2026, including a net income increase to $8.1 million and adjusted EBITDA up to $36.4 million compared to the previous year. The company completed an IPO raising $206.7 million used to significantly reduce debt, enhancing financial flexibility. Growth strategies include converting retai…

APC
Kaspi.kz 1Q 2026 Financial Results
May 11, 2026
Sofia Navarro
Press Releases

Kaspi.kz 1Q 2026 Financial Results

Kaspi.kz announced robust financial results for Q1 2026 with a 41% year-over-year growth in e-Commerce gross merchandise value and a 9% increase in adjusted EBITDA. The company highlighted increased consumer purchase frequency and improved monetization, particularly in advertising and delivery services. Kaspi.kz is expanding internationally with si…

KSPI
OLAPLEX Reports First Quarter 2026 Results
May 11, 2026
Priya Menon
Press Releases

OLAPLEX Reports First Quarter 2026 Results

Olaplex Holdings, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a 2.5% increase in net sales to $99.4 million but a net loss of $5.3 million compared to net income in the prior year period. The company highlighted positive sales trends driven by the launch of No. 3 PLUS and progress in its transformation…

OLPX
Elme Communities Provides Update On Liquidation Activities
May 11, 2026
Sofia Navarro
Press Releases

Elme Communities Provides Update On Liquidation Activities

Elme Communities provided an update on its ongoing liquidation process, having sold five properties in 2026 and entering agreements for four more, targeting completion of all sales by mid-2026. The company adjusted its estimated total liquidating distributions to $16.74-$17.02 per share, down from prior estimates, due to softer market conditions an…

ELME
Nova Winter Freight Season Complete
May 11, 2026
Nina Shah
Press Releases

Nova Winter Freight Season Complete

Nova Minerals Limited successfully completed its 2026 winter freight mobilization to its Estelle Project in Alaska, delivering essential heavy equipment and supplies for mining and processing antimony ore. The company is now poised to begin construction of new infrastructure including access trails, an airstrip expansion, and an ore sorting and pro…

NVA
Liquidia Corporation Reports First Quarter 2026 Financial Results
May 11, 2026
Nina Shah
Press Releases

Liquidia Corporation Reports First Quarter 2026 Financial Results

Liquidia Corporation reported first quarter 2026 financial results highlighting approximately $130 million in net product sales of YUTREPIA®, sustained patient uptake, and net income of $53 million—marking its third consecutive profitable quarter. The company continues to advance clinical programs for its pulmonary hypertension treatments and expan…

LQDA
Certara Reports First Quarter 2026 Financial Results
May 11, 2026
Jordan Park
Press Releases

Certara Reports First Quarter 2026 Financial Results

Certara, Inc. reported its Q1 2026 financial results with 1% revenue growth to $106.9 million driven by 7% growth in software revenue, while services revenue declined 4%. The company posted a net loss of $8.8 million compared to net income of $4.7 million a year ago, primarily due to higher operating expenses related to acquisitions, employee costs…

CERT